Germline polymorphisms and the risk of therapy-related myeloid neoplasms
Publication date: Available online 11 February 2019Source: Best Practice &Research Clinical HaematologyAuthor(s): Koichi TakahashiAbstractTherapy-related myeloid neoplasms (t-MNs) are one of the lethal complications from cytotoxic chemotherapy/radiation therapy. There is substantial variability in the risk of developing t-MNs among individuals who receive the same level of exposures and it has been widely suspected that germline polymorphisms may influence the risk and account for the variability. As the number of cancer survivors increases, effectively identifying an individual with a high risk of developing t-MNs is crucial. Here, we review the previous studies that investigated the association between germline polymorphisms and the risk of t-MNs. Through this process, we also discuss inconsistencies among the results that stem from the difficulties in conducting an appropriate study to link germline polymorphisms with a disease like t-MN that is rare and has a strong association with external exposures.
AbstractHigh-grade endometrial carcinomas are a heterogeneous group of clinically aggressive tumours. They include FIGO grade 3 endometrioid adenocarcinoma, uterine papillary serous carcinoma (UPSC), clear cell carcinoma, undifferentiated carcinoma and carcinosarcomas or malignant mixed Mullerian tumour (MMMT). The aim of this study is to look at clinicopathological features and survival outcomes of high-grade endometrial cancers of the uterus in our centre. A tertiary care centre in India. The study design is retrospective with survival analysis. We did a retrospective analysis of all patients admitted with a diagnosis of...
Conclusion: VMAT combined with IC/IS BT can result in satisfactory curative outcomes and low incidences of late radiation enterocolitis and cystitis in CC treatment.
Conclusion.SSAs, alone and in combination, are common treatments for advanced lung NETs. Patients have additional treatment options and relatively long survival compared with patients with other advanced cancers. Treatment pattern assessment following approval of newer treatments is needed.Implications for Practice.Somatostatin analogs (SSAs), cytotoxic chemotherapy, EBRT, liver‐directed therapy, and targeted therapies are common treatments for locally advanced/metastatic (typical/atypical) lung neuroendocrine tumors (NETs). SSAs alone or in combination with other treatment modalities were the most common first‐ and se...
Conditions: Bilateral Breast Carcinoma; Breast Carcinoma; HER2/Neu Negative; Mastectomy Patient; Recurrent Breast Carcinoma; Triple-Negative Breast Carcinoma Interventions: Drug: ATR Kinase Inhibitor M6620; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Radiation: Radiation Therapy Sponsor: National Cancer Institute (NCI) Not yet recruiting
This study promotes the feasibility of hepatic resection following SIRT. Resin microspheres appear to preferentially distribute at the tumour periphery and may enhance tumour regression.
ConclusionThe results showed lower incremental costs of DBT vs. DM, compared to what is found in previous cost analyses of DBT and DM. However, the incremental costs were still higher for DBT compared with DM after including recall costs. Further studies with long-term treatment data are needed to understand the complete costs of implementing DBT in screening.
Authors: Shinde A, Li R, Amini A, Chen YJ, Cristea M, Wang W, Wakabyashi M, Han E, Yashar C, Albuquerque K, Beriwal S, Glaser S Abstract BACKGROUND: Vulvar cancer with pelvic nodal involvement is considered metastatic (M1) disease per AJCC staging. The role of definitive therapy and its resulting impact on survival have not been defined. PATIENTS AND METHODS: Patients with pelvic lymph node-positive vulvar cancer diagnosed in 2009 through 2015 were evaluated from the National Cancer Database. Patients with known distant metastatic disease were excluded. Logistic regression was used to evaluate use of surgery an...
Conditions: Metastatic Pancreatic Adenocarcinoma; Refractory Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8 Interventions: Biological: Nivolumab; Radiation: Radiation Therapy; Drug: TLR9 Agonist SD-101 Sponsors: University of California, Davis; National Cancer Institute (NCI); Bristol-Myers Squibb; Dynavax Technologies Corporation Not yet recruiting